Amplexor raises funds for childhood cancer research in the Netherlands

09 July 2018

Amplexor raises funds for childhood cancer research in the Netherlands

9 July 2018

On 1 July and for the second year in a row, Amplexor sponsored the annual Run for Kika Marathon in Eindhoven, Netherlands.

This year, Amplexor team was able to not only increase the number of participants but also to surpass 2017’s fundraising efforts. Our team had 12 runners participating which included a young participant – the child of one of our colleagues who took part in the KidsRun. And it is all for a great cause – the Kika Foundation, whose goal is to see children be cancer free by supporting the scientific research and development of more effective treatments. 

As part of Amplexor’s corporate social responsibility, we integrate our social, economic, and environmental responsibilities into our activities and encourage our employees to participate in community initiatives. It is our belief that as well as contributing to larger social goals, fundraising and charity activities bring positive results to employee engagement and performance, boost morale and promote teamwork.

According to Kika, specialist research programs are evolving towards new treatment methods and higher possibilities to cure children's cancer with less side effects. The event is held each year at seven cancer research locations across the Netherlands, where participants can raise funds and run as individuals or as a team with friends, family or colleagues. This event is something everyone can enjoy, running 10K or 5K and even kids can participate in a 400M KidsRun. In addition to the marathon, the event also includes food trucks, games and a special stage program for everyone to enjoy.

The Amplexor team in Eindhoven is proud to make a difference for children living with cancer and their families, having contributed to the total raised of almost 1 million euro. Kika works with the Dutch Cancer Society using the funds raised from each marathon to increase childhood cancer cure rates to 95% by supporting innovative research and development.

Find out more about our corporate social responsibility initiatives